Breaking News

Tweet TWEET

BSD Medical Announces Dr. James G. Carlisle and the MicroThermX® Microwave Ablation System Profiled in Healthcare Heroes

  BSD Medical Announces Dr. James G. Carlisle and the MicroThermX® Microwave
  Ablation System Profiled in Healthcare Heroes Article

Business Wire

SALT LAKE CITY -- January 17, 2013

BSD Medical Corporation (NASDAQ:BSDM) (Company or BSD) (www.BSDMedical.com), a
leading provider of medical systems that utilize targeted heat therapy to
treat cancer, today announced that Dr. James G. Carlisle and his pioneering
work with BSD's MicroThermX^® Microwave Ablation System (MicroThermX^®) were
profiled in a recent issue of Utah Business. (Cutler, S, Lewis, DI, Francom,
“Healthcare Heroes the Quiet Champions of Healing and Hope.”)  The annual
publication by Utah Business is devoted to health care workers who exemplify a
devotion to bringing health and hope to patients. The authors discussed the
innovative technology incorporated into the MicroThermX^® and explained that,
"This innovation surrounds a tumor with small antennas and heats it with
microwaves until the tumor cells are destroyed." The authors explained that
Dr. Carlisle was the first MicroThermX^® specialist in Utah and is one of
Utah's leading providers of groundbreaking treatments that improve care and
make recovery easier for cancer patients. The authors noted that Dr. Carlisle
uses the MicroThermX^® as a method to improve patient outcome and reduce the
negative impact of the treatment. The article is available at:
http://dev.utahbusiness.com/articles/view/healthcare_heroes_1.

About the MicroThermX^® Microwave Ablation System

The MicroThermX^® is a compact, mobile, state-of-the-art, proprietary system
that includes a microwave generator, single-patient-use disposable antennas,
and a thermistor-based temperature monitoring system. The innovative design is
the first of its kind that allows delivery of higher power levels using a
single generator. The MicroThermX^® utilizes innovative synchronous phased
array technology that was developed and patented by BSD to provide larger and
more uniform zones of ablation during a single procedure. The MicroThermX^®
introduces into the Company’s product line an innovative, high-end disposable
that is used in each ablation treatment, and will provide a significant
ongoing revenue stream. The soft tissue ablation world market potential is
estimated to exceed $2.3 billion. The U.S. Food and Drug Administration (FDA)
has granted the Company a 510(k) clearance to market the MicroThermX^® for
ablation of soft tissue. BSD has also received CE Marking for the
MicroThermX^® System.

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems
to treat cancer and benign diseases using heat therapy, which is delivered
using focused radiofrequency (RF) and microwave energy. BSD’s product lines
include both hyperthermia and ablation treatment systems. BSD’s hyperthermia
cancer treatment systems, which have been in use for several years in the
United States, Europe and Asia, are used to treat certain tumors with heat
(hyperthermia) while increasing the effectiveness of other therapies such as
radiation therapy. BSD’s microwave ablation system has been developed as a
stand-alone therapy to employ precision-guided microwave energy to ablate
(destroy) soft tissue. The Company has developed extensive intellectual
property, multiple products in the market and established distribution in the
United States, Europe and Asia. Certain of the Company’s products have
received regulatory approvals and clearances in the United States, Europe and
China. For further information visit BSD Medical's website at
www.BSDMedical.com.

Statements contained in this press release that are not historical facts are
forward-looking statements, as defined in the Private Securities Litigation
Reform Act of 1995. All forward-looking statements are subject to risks and
uncertainties detailed in the Company's filings with the Securities and
Exchange Commission. These forward-looking statements speak only as of the
date on which such statements are made, and the Company undertakes no
obligation to update such statements to reflect events or circumstances
arising after such date.

Contact:

BSD Medical Corporation
William (Bill) S. Barth, 801-972-5555
investor@bsdmc.com
fax: 801-972-5930
 
Press spacebar to pause and continue. Press esc to stop.